Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zeo ScientifiX ( (ZEOX) ) has shared an update.
On June 24, 2025, ZEO ScientifiX announced the ZEO Masterclass, aimed at educating Florida physicians about the upcoming SB-1768 law effective July 1, 2025. This law allows MDs and DOs to offer non-FDA-approved stem cell therapies under strict compliance, impacting specialties like pain management and orthopedics. The masterclass will provide training on legal compliance, clinical integration, and ethical guidelines, positioning ZEO as a leader in regenerative medicine and supporting physicians in adopting new therapeutic solutions.
More about Zeo ScientifiX
ZEO ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics. The company is committed to advancing regenerative medicine and biologic therapeutics, offering proprietary products like Zofin™ and Patient Pure X™. ZEO operates an FDA-registered, cGMP-compliant laboratory and has recently launched a collaborative product for hair regrowth.
Average Trading Volume: 5,900
Technical Sentiment Signal: Buy
Current Market Cap: $15.29M
See more data about ZEOX stock on TipRanks’ Stock Analysis page.